Skip to main content
Protagenic Therapeutics, Inc.\new logo

Protagenic Therapeutics, Inc.\new — Investor Relations & Filings

Ticker · PTIX ISIN · US74365N2027 LEI · 549300KPBYAVJLPDKB70 US Professional, scientific and technical activities
Open in API
Filings indexed 678 across all filing types
Latest filing 2021-06-21 Capital/Financing Update
Country US United States of America
Listing US PTIX

About Protagenic Therapeutics, Inc.\new

https://protagenic.com/

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based therapeutics for stress-related disorders. The company's core technology is its TCAP (teneurin C-terminal associated peptide) platform, which utilizes neuropeptides to regulate the brain's stress response at a cellular level. This approach aims to counteract the 'Stress Feedback Loop' implicated in various neuropsychiatric and neurodegenerative conditions. Its lead drug candidate, PT00114, a synthetic TCAP, is being developed as a potential first-in-class treatment for disorders such as anxiety and depression.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to a Form S-3 Registration Statement filed with the SEC by Protagenic Therapeutics, Inc. It is a regulatory filing related to securities registration under the Securities Act of 1933. The document includes an exhibit index, signatures, and legal opinions, but does not contain financial statements or management discussion and analysis. It is not an annual report, earnings release, or any other financial report type. It is a filing related to capital raising and securities registration, which fits the category of Capital/Financing Update (CAP). The document is over 10,000 characters and is a substantive filing, not just an announcement or certification. Therefore, the best classification is CAP with high confidence.
2021-06-21 English
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document into any specific filing category. According to the rules, if a document does not neatly fit into any category, the fallback classification is Regulatory Filings (RNS).
2021-06-11 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for sale to the public. It includes detailed information about the types of securities to be offered, the maximum aggregate offering price, and the plan of distribution. The document is a registration statement prospectus, not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or a brief notice, confirming it is the actual filing of a registration statement.
2021-06-04 English
Director's Dealing 2021
Director's Dealing
2021-06-04 English
Director's Dealing 2021
Director's Dealing
2021-06-02 English
Director's Dealing 2021
Director's Dealing
2021-06-01 English

Browse filings by year

30 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.